Clinical impact of the interstitial lung disease multidisciplinary service

Respirology

Volumn 21, Issue 8, 2016, Pages 1438-1444

  Jo, Helen E ^a,b   Glaspole, Ian N ^c,d   Levin, Kovi C ^c   McCormack, Samuel R ^a   Mahar, Annabelle M ^a   Cooper, Wendy A ^a,b   Cameron, Rhoda ^c   Ellis, Samantha J ^c   Cottee, Alice M ^a,b   Webster, Susanne E ^a   Troy, Lauren K ^a,b   Torzillo, Paul J ^a,b   Corte, Peter ^a   Symons, Karen M ^c   Taylor, Nicole ^a   Corte, Tamera J ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b University of Sydney   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

idiopathic interstitial pneumonia; idiopathic pulmonary fibrosis; interstitial lung disease; multidisciplinary

Indexed keywords

AGED; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENERAL PRACTITIONER; HEALTH SERVICE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG DIFFUSION CAPACITY OF CARBON MONOXIDE; LUNG RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTIDISCIPLINARY SERVICE; PATIENT REFERRAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY SPECIALIST; DISEASE MANAGEMENT; INTERDISCIPLINARY COMMUNICATION; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT CARE; STANDARDS; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME;

AGED; AUSTRALIA; DISEASE MANAGEMENT; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERDISCIPLINARY COMMUNICATION; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PATIENT CARE TEAM; QUALITY IMPROVEMENT; REFERRAL AND CONSULTATION; TREATMENT OUTCOME;

EID: 84991492584     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12850     Document Type: Article

References (27)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002; 165: 277–304.
2. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA et al. Fibrosis AEJACoIP. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788–824.
3. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU et al. An Official American Thoracic Society/European Respiratory Society Statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013; 188: 733–48.
4. Aziz ZA, Wells AU, Hansell DM, Bain GA, Copley SJ, Desai SR, Ellis SM, Gleeson FV, Grubnic S, Nicholson AG et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax 2004; 59: 506–11.
5. Nicholson AG, Addis BJ, Bharucha H, Clelland CA, Corrin B, Gibbs AR, Hasleton PS, Kerr KM, Ibrahim NB, Stewart S et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004; 59: 500–5.
6. Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, Verschakelen J, Laurent F, Nicholson AG, Verbeken EK et al. Idiopathic Pulmonary Fibrosis International Group Exploring NAIAsg Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur. Respir. J. 2008; 31: 585–91.
7. Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am. J. Respir. Crit. Care Med. 2004; 170: 904–10.
8. Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am. J. Respir. Crit. Care Med. 2007; 175: 1054–60.
9. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV. Prognosis of fibrotic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2007; 175: 705–11.
10. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 531–7.
11. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ, Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968–77.
12. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083–92.
13. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y et al. Investigators IT. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071–82.
14. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 2006; 354: 2655–66.
15. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann. Intern. Med. 2000; 132: 947–54.
16. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, Meehan RT, Brown KK. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006; 130: 30–6.
17. Selman M, Pardo A, King TE Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am. J. Respir. Crit. Care Med. 2012; 186: 314–24.
18. Yoshida K, Ando M, Sakata T, Araki S. Prevention of summer-type hypersensitivity pneumonitis: effect of elimination of Trichosporon cutaneum from the patients' homes. Arch. Environ. Health 1989; 44: 317–22.
19. Troy L, Glaspole I, Goh N, Zappala C, Hopkins P, Wilsher M, Moodley Y, Corte T. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur. Respir. J. 2014; 43: 1529–30.
20. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE Jr, Wolters PJ et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur. Respir. J. 2013; 42: 750–7.
21. Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am. J. Respir. Crit. Care Med. 2011; 184: 842–7.
22. Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am. J. Respir. Crit. Care Med. 2015; 192: e3–19.
23. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 2393–9.
24. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746–52.
25. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, Murray S, Kazerooni EA, Gross BH, Lynch JP et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 1084–90.
26. Kreider ME, Hansen-Flaschen J, Ahmad NN, Rossman MD, Kaiser LR, Kucharczuk JC, Shrager JB. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann. Thorac. Surg. 2007; 83: 1140–4.
27. Lettieri CJ, Veerappan GR, Helman DL, Mulligan CR, Shorr AF. Outcomes and safety of surgical lung biopsy for interstitial lung disease. Chest 2005; 127: 1600–5.